PT - JOURNAL ARTICLE AU - Kaneko, Yudai AU - Sugiyama, Akira AU - Tanaka, Toshiya AU - Fukui, Kazushige AU - Taguchi, Akashi AU - Nakayama, Aya AU - Koga, Kazumasa AU - Kishi, Yoshiro AU - Daming, Wang AU - Qian, Chungen AU - Xia, Fuzhen AU - He, Fan AU - Zheng, Liang AU - Yu, Yi AU - Wada, Youichiro AU - Wada, Yoshiaki AU - Kodama, Tatsuhiko AU - Kawamura, Takeshi TI - The serological diversity of serum IgG/IgA/IgM against the SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan AID - 10.1101/2021.06.17.21258858 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.17.21258858 4099 - http://medrxiv.org/content/early/2021/06/25/2021.06.17.21258858.short 4100 - http://medrxiv.org/content/early/2021/06/25/2021.06.17.21258858.full AB - Objectives To compare the temporal changes of IgM, IgG, and IgA antibodies against the SARS-CoV-2 nucleoprotein, S1 subunit, and receptor binding domain and neutralizing antibodies (NAbs) against SARS-CoV-2 in patients with COVID-19.Methods A total of five patients in Nissan Tamagawa Hospital, Tokyo, Japan confirmed COVID-19 from August 8, 2020 to August 14, 2020 were investigated. Serum samples were acquired multiple times from 0 to 76 days after symptom onset. Using a fully automated CLIA analyzer, we measured the levels of IgG, IgA, and IgM against the SARS-CoV-2 N, S1, and RBD and NAbs against SARS-CoV-2.Results The levels of IgG antibodies against SARS-CoV-2 structural proteins increased over time in all cases but IgM and IgA levels against SARS-CoV-2 showed different increasing trends among individuals in the early stage. In particular, we observed IgA antibodies increasing before IgG and IgM in 3/5 cases. The NAb levels against SARS-CoV-2 increased and kept above 10 AU/mL more than around 70 days after symptom onset in all cases. Furthermore, in the early stage, NAb levels were more than cut off value in 4/5 COVID-19 patients some of whose antibodies against RBD didn’t exceed 10 AU/mL.Conclusions Our findings indicate that patients with COVID-19 should be examined for IgG, IgA and IgM antibodies against SARS-CoV-2 structural proteins and NAbs against SARS-CoV-2 in addition to conventional antibody testing methods for SARS-CoV-2 (IgG and IgM kits) to analyze the diversity of patients’ immune mechanisms.Competing Interest StatementThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: 2019-nCoV IgM and IgG chemiluminescence immunoassay (CLIA) kits, Covid-2019 IgG/IgA/IgM Kit against N/S1/RBD antigen, and iFlash-2019- nCoV NAb were sponsored by Medical & Biological Laboratories Co., Ltd. and Shenzhen YHLO Biotech Co., Ltd.Funding StatementThis study was supported by grants from the Peace Winds Japan, Kowa Co., the Research Center for Advanced Science and Technology, and Kodama laboratory in the University of Tokyo. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed at the University of Tokyo and Nissan Tamagawa Hospital approved by their ethics committee (protocol number R2-05 and Tama2020-003).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, T. K., upon reasonable request.